RxDoctor Payments Data

Rayan Hourani, MD

Interventional Cardiology · El Cajon, CANPI 1265638811

Payments from drug & device makers

$20,400in general payments, 2019–2025

Across 652 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$2K
  • Novartis$1K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Edwards Lifesciences$1K
  • plus $10K from 46 others

What the payments were for

  • Speaking & faculty fees$3502%
  • Food & beverage$19,98098%
  • Education$690%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,400 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$323,615
Medicare patients
891
Services billed
2,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban485$563,623
EntrestoSacubitril/Valsartan392$466,116
XareltoRivaroxaban408$393,312
BrilintaTicagrelor226$158,283
FarxigaDapagliflozin Propanediol130$130,239
JardianceEmpagliflozin109$92,869
Repatha SureclickEvolocumab57$53,732
MultaqDronedarone Hcl29$49,040
Repatha SyringeEvolocumab25$17,012
Praluent PenAlirocumab21$13,793
VascepaIcosapent Ethyl30$12,929
LivaloPitavastatin Calcium18$12,718
DapagliflozinDapagliflozin Propanediol17$9,348
Pitavastatin Calcium18$7,650
Ranolazine ErRanolazine127$7,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$720$563,623485 claims
NovartisEntresto$1,164$466,116392 claims
Johnson & JohnsonXarelto$1,121$393,312408 claims
AstraZenecaBrilinta, Farxiga$1,083$288,522356 claims
Boehringer IngelheimJardiance$464$92,869109 claims
Sanofi-aventis U.S. LLCMultaq$698$49,04029 claims
Kowa Pharmaceuticals America, Inc.Livalo$14$12,71818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →